Phentermine/topiramate
| Combination of | |
|---|---|
| Phentermine | Appetite suppressant/stimulant of the amphetamine and phenethylamine class |
| Topiramate | Anticonvulsant (extended release formulation is used) |
| Clinical data | |
| Pronunciation | /kjuːsɪˈmiːə/ kew-sim-EE-ə |
| Trade names | Qsymia |
| AHFS/Drugs.com | Professional Drug Facts |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| (verify) | |
Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.
Common side effects include tingling, dizziness, trouble sleeping, and constipation. Serious side effects may include suicide, abuse. Use is not recommended during pregnancy. Phentermine is a stimulant and appetite suppressant. Topiramate is an anticonvulsant that has weight loss side effects. The exact mechanism of action for both drugs is unknown.
Phentermine/topiramate was approved for medical use in the United States in 2012. In October 2012, approval was denied in Europe, due to concerns regarding safety.